Research Study for Grave's Disease

Official Title A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves’ Disease

Purpose

1. To find out how safe the study drug is and how well people with Graves’ disease can handle taking one or more doses.

2. To describe how the body absorbs, uses, and removes a single IV or subcutaneous dose, or several subcutaneous doses, of MER511 in people with Graves’ disease.

3. To check whether the body creates an immune response after a single IV or subcutaneous dose, or several subcutaneous doses, of MER511 in people with Graves’ disease.

 

Could this study be right for you?

1. Grave's disease diagnosis

2. Taking methimazole or propylthiouracil

3. Weigh at least 110 lbs

4. Women of childbearing potential must agree to use contraceptive methods and avoid egg donation during the study; Men with partners of childbearing potential must agree to use a condom or abstinence and avoid sperm donation during the study

Age Range

18 - 55 years

Contact Information

Ohio State University Carepoint East

Lindsey Aldrich

lindsey.aldrich@osumc.edu

614-814-0772